- Parties: The plaintiffs were Janssen Inc. and Actelion Pharmaceuticals Ltd. The defendant was Pharmascience Inc.

- Subject Matter: This Federal Court matter involves an action commenced under subsection 6(1) of the Patented Medicines (Notice of Compliance) Regulations, in which the Plaintiffs allege that Pharmascience Inc.'s generic macitentan 10 mg film-coated tablet product (the "PMS Product"), if approved by Health Canada, will infringe Canadian Patent Nos. 2,659,770 and 2,621,273, both listed on the Patent Register in relation to the brand product OPSUMIT. The Defendant denies infringement, asserting that the PMS Product lacks essential elements of the asserted patent claims, and has raised a Gillette Defence in its Amended Statement of Defence. This case is ongoing.

- Date: The hearing was set on March 26, 2026.

- Venue: This was a federal case before the Federal Court.

- Amount: No financial award was specified.